Form 8-K · Current Report · Filed 2025-01-13
Moderna Reports Preliminary 2024 Financial Results and Provides 2025 Outlook
On January 13, 2025, Moderna, Inc. reported preliminary unaudited financial results for the fiscal year ended December 31, 2024. The company generated product sales of $3.0 to $3.1 billion and an ending cash balance of approximately $9.5 billion. Moderna updated its 2025 financial framework, projecting revenue between $1.5 to $2.5 billion, a reduction in cash cost expenses by $1.0 billion, and an ending cash balance of approximately $6.0 billion. Moderna also highlighted progress across its pipeline, including updates on respiratory vaccines, latent and other vaccines, oncology therapeutics, and rare disease therapeutics.
- Filer
- Moderna Inc. MRNA · NASDAQ
- Filed
- Accession
- 0001682852-25-000002
- CIK
- 0001682852
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Regulation FD Disclosure
Financial Statements and Exhibits
Market reaction
Close before filing
$42.25
Next session
-18.4%
Since filing
+29.8%
Latest close
$54.82
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from MRNA reporting the same item, with the next session's move:
Exhibits (1)
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Never miss another MRNA filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.